Menu Search
Equities

Sensus Healthcare Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
5TX:STU

Sensus Healthcare Inc

Actions
  • Price (EUR)3.96
  • Today's Change-0.10 / -2.46%
  • Shares traded0.00
  • 1 Year change-26.67%
  • Beta1.2021
Data delayed at least 15 minutes, as of Feb 11 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Sensus Healthcare, Inc. is a medical device company that is engaged in the development and delivery of non-invasive treatments for skin cancer and keloids. The Company, leveraging its superficial radiotherapy (SRT and IG-SRT) technology, provides healthcare providers with a patient-centric treatment platform. Its products and services include SRT-100, SRT-100 Vision, SRT-100+, Sentinel service program and others. The SRT-100 is a photon x-ray low energy SRT system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides customers with additional options compared to the SRT-100 base model. These additional options allow for dedicated treatment planning and full treatment progression documentation in a patient’s record. The SRT-100+ offers all the same features as the SRT-100, with the addition of remote diagnostics and other features.

  • Revenue in USD (TTM)35.61m
  • Net income in USD-3.01m
  • Incorporated2010
  • Employees35.00
  • Location
    Sensus Healthcare Inc851 Broken Sound Pkwy NW Ste 215BOCA RATON 33487-3635United StatesUSA
  • Phone+1 (561) 922-5808
  • Fax+1 (561) 948-2071
  • Websitehttps://sensushealthcare.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.